Eric Deutsch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6330663/publications.pdf

Version: 2024-02-01

286	21,379	28736 57	13274 135
papers	citations	h-index	g-index

340	340	340	39329
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Deciphering the Dynamic Molecular Program of Radiation-Induced Endothelial Senescence. International Journal of Radiation Oncology Biology Physics, 2022, 112, 975-985.	0.4	8
2	Personalised radiation therapy taking both the tumour and patient into consideration. Radiotherapy and Oncology, 2022, 166, A1-A5.	0.3	7
3	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 315-324.	15.2	225
4	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	7.7	10
5	A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer. Cancers, 2022, 14, 1697.	1.7	7
6	TGFÎ² receptor inhibition unleashes interferon-Î² production by tumor-associated macrophages and enhances radiotherapy efficacy. , 2022, 10, e003519.		13
7	Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments. International Journal of Radiation Oncology Biology Physics, 2022, 113, 602-613.	0.4	11
8	How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation. Cancers, 2022, 14, 1705.	1.7	4
9	Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveys. ESMO Open, 2022, 7, 100451.	2.0	4
10	Providing Patients with Locally Advanced Cervical Cancer Access to Brachytherapy: Experience from a Referral Network for Women Treated in Overseas France. Cancers, 2022, 14, 2935.	1.7	1
11	Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials. European Journal of Cancer, 2022, 171, 242-258.	1.3	3
12	NADPH oxidase DUOX1 sustains TGF-Î²1 signalling and promotes lung fibrosis. European Respiratory Journal, 2021, 57, 1901949.	3.1	30
13	Reinventing radiation therapy with machine learning and imaging bio-markers (radiomics): State-of-the-art, challenges and perspectives. Methods, 2021, 188, 44-60.	1.9	29
14	AI-driven quantification, staging and outcome prediction of COVID-19 pneumonia. Medical Image Analysis, 2021, 67, 101860.	7.0	111
15	Analysis of Radiation Dose/Volume Effect Relationship for Anorectal Morbidity in Children Treated for Pelvic Malignancies. International Journal of Radiation Oncology Biology Physics, 2021, 109, 231-241.	0.4	7
16	Drugâ€“Radiotherapy Combination Trial Developmentsâ€”Response. Clinical Cancer Research, 2021, 27, 356-356.	3.2	0
17	Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patientsâ€™ health quality perception. Journal of Contemporary Brachytherapy, 2021, 13, 263-272.	0.4	3
18	Radiation oncology in the new virtual and digital era. Radiotherapy and Oncology, 2021, 154, A1-A4.	0.3	8

#	Article	IF	Citations
19	Dosimetric characterisation and application to radiation biology of a kHz laser-driven electron beam. Applied Physics B: Lasers and Optics, 2021, 127, 1.	1.1	8
20	COVID-19-Associated Pneumonia: Radiobiological Insights. Frontiers in Pharmacology, 2021, 12, 640040.	1.6	4
21	(Chemo)Radiotherapyâ€“Immunotherapy Combinations: Time to Get Tailored?. Clinical Cancer Research, 2021, 27, 3815-3817.	3.2	4
22	Could Protons Promote Tumor Control by Avoiding Lymphopenia?. Journal of Thoracic Oncology, 2021, 16, e39-e41.	0.5	2
23	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Research, 2021, 81, 2888-2902.	0.4	66
24	Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot. International Journal of Radiation Oncology Biology Physics, 2021, 110, 947-956.	0.4	9
25	Development of a Machine Learning Classifier Based on Radiomic Features Extracted From Post-Contrast 3D T1-Weighted MR Images to Distinguish Glioblastoma From Solitary Brain Metastasis. Frontiers in Oncology, 2021, 11, 638262.	1.3	15
26	Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiotherapy and Oncology, 2021, 160, 159-165.	0.3	67
27	Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?. Clinical and Translational Radiation Oncology, 2021, 29, 79-84.	0.9	1
28	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death and Differentiation, 2021, 28, 3297-3315.	5.0	31
29	Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1283-1294.	0.4	23
30	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. Clinical Colorectal Cancer, 2021, 20, 279-287.	1.0	6
31	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ˜†. Annals of Oncology, 2021, 32, 1087-1100.	0.6	100
32	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. Radiotherapy and Oncology, 2021, 154, 125-127.	0.3	7
33	Brain Tumor Segmentation with Self-ensembled, Deeply-Supervised 3D U-Net Neural Networks: A BraTS 2020 Challenge Solution. Lecture Notes in Computer Science, 2021, , 327-339.	1.0	39
34	Increasing global accessibility to high-level treatments for cervical cancers. Gynecologic Oncology, 2021, , .	0.6	11
35	Radiobiology: Foundation and New Insights in Modeling Brachytherapy Effects. Seminars in Radiation Oncology, 2020, 30, 4-15.	1.0	10
36	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1147-1157.	3.3	103

#	Article	IF	Citations
37	Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2020, 26, 6429-6436.	3.2	14
38	Imagerie mÃ©dicale computationnelle (radiomique) : principes et potentiel en onco-pneumologie. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S307-2S313.	0.0	1
39	Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. , 2020, 8, e001429.		46
40	Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics. Scientific Reports, 2020, 10, 12340.	1.6	138
41	Brachytherapy Issues and Priorities in the Context of the Coronavirus Disease 2019 (COVID-19) Outbreak. Advances in Radiation Oncology, 2020, 5, 640-643.	0.6	9
42	Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma. , 2020, 8, e000627.		13
43	Improving Radiotherapy Workflow Through Implementation of Delineation Guidelines & AI-Based Annotation. International Journal of Radiation Oncology Biology Physics, 2020, 108, e315.	0.4	6
44	A Blinded Prospective Evaluation Of Clinical Applicability Of Deep Learning-Based Auto Contouring Of OAR For Head and Neck Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, e780-e781.	0.4	4
45	Dosimetry-Driven Quality Measure of Brain Pseudo Computed Tomography Generated From Deep Learning for MRI-Only Radiation Therapy Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2020, 108, 813-823.	0.4	18
46	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clinical Cancer Research, 2020, 26, 4723-4736.	3.2	23
47	Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy. Journal of Clinical Medicine, 2020, 9, 1441.	1.0	14
48	Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models. British Journal of Cancer, 2020, 123, 762-771.	2.9	11
49	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. European Journal of Cancer, 2020, 135, 103-112.	1.3	11
50	Innate immune receptor NOD2 mediates LGR5 ⁺ intestinal stem cell protection against ROS cytotoxicity via mitophagy stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1994-2003.	3.3	63
51	Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy. Gynecologic Oncology, 2020, 157, 644-648.	0.6	18
52	Interaction between the Number of Chemotherapy Cycles and Brachytherapy Dose/Volume Parameters in Locally Advanced Cervical Cancer Patients. Journal of Clinical Medicine, 2020, 9, 1653.	1.0	10
53	Dual oxidase 1 limits the IFNÎ³-associated antitumor effect of macrophages. , 2020, 8, e000622.		17
54	Radiotherapyâ€“immunotherapy combinations â€“ perspectives and challenges. Molecular Oncology, 2020, 14, 1529-1537.	2.1	94

#	Article	IF	Citations
55	Stereotactic Lung Irradiation in Mice Promotes Long-Term Senescence and Lung Injury. International Journal of Radiation Oncology Biology Physics, 2020, 106, 1017-1027.	0.4	17
56	AGuIX^{Â®} from bench to bedsideâ€"Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 2019, 92, 20180365.	1.0	86
57	Fast dose fractionation using ultra-short laser accelerated proton pulses can increase cancer cell mortality, which relies on functional PARP1 protein. Scientific Reports, 2019, 9, 10132.	1.6	48
58	Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1141-1152.	0.4	17
59	Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncology, The, 2019, 20, e452-e463.	5.1	150
60	Brachytherapy: An overview for clinicians. Ca-A Cancer Journal for Clinicians, 2019, 69, 386-401.	157.7	150
61	Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer. Cancer Investigation, 2019, 37, 29-38.	0.6	2
62	CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFÎ±-Mediated Resistance. Cancer Immunology Research, 2019, 7, 376-387.	1.6	79
63	Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?. Annals of Oncology, 2019, 30, 879-881.	0.6	11
64	Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. International Journal of Radiation Oncology Biology Physics, 2019, 104, 365-373.	0.4	26
65	Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. OncoImmunology, 2019, 8, e1574197.	2.1	16
66	Plerixafor for the Treatment of WHIM Syndrome. New England Journal of Medicine, 2019, 380, e25.	13.9	4
67	The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features. Scientific Reports, 2019, 9, 4329.	1.6	80
68	Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. EBioMedicine, 2019, 43, 253-260.	2.7	37
69	Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer. Brachytherapy, 2019, 18, 370-377.	0.2	7
70	Role of image-guided biopsy and radiomics in the age of precision medicine. Chinese Clinical Oncology, 2019, 8, 57-57.	0.4	15
71	Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2. JCO Clinical Cancer Informatics, 2019, 3, 1-10.	1.0	6
72	Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. Radiotherapy and Oncology, 2019, 130, 89-96.	0.3	23

#	Article	IF	Citations
73	CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. European Respiratory Journal, 2018, 51, 1702120.	3.1	114
74	Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters. International Journal of Radiation Oncology Biology Physics, 2018, 101, 411-420.	0.4	34
75	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. European Journal of Cancer, 2018, 92, 1-10.	1.3	14
76	Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?. European Respiratory Journal, 2018, 51, 1701737.	3.1	32
77	Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. Clinical and Translational Radiation Oncology, 2018, 10, 47-52.	0.9	36
78	Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	6.0	3,689
79	Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 619-628.	1.2	7
80	Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma. Brachytherapy, 2018, 17, 221-226.	0.2	13
81	A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 187-195.	3.3	25
82	Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy. Radiotherapy and Oncology, 2018, 126, 116-124.	0.3	16
83	Brachytherapy for conservative treatment of invasive penile carcinoma in older patients: Single institution experience. Journal of Geriatric Oncology, 2018, 9, 275-278.	0.5	5
84	Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 9-16.	0.6	13
85	Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients. Frontiers in Oncology, 2018, 8, 336.	1.3	26
86	Macrophages in radiation injury: a new therapeutic target. OncoImmunology, 2018, 7, e1494488.	2.1	48
87	Combining radiation therapy and cancer immune therapies: From preclinical findings to clinical applications. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 567-580.	0.6	24
88	Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 362-372.	0.4	48
89	Pharmacological modulation of radiation-induced oral mucosal complications. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 429-437.	0.6	18
90	â€œRadiobiology of Proton Therapyâ€• Results of an international expert workshop. Radiotherapy and Oncology, 2018, 128, 56-67.	0.3	85

#	Article	IF	Citations
91	Radiomics in Nuclear Medicine Applied to Radiation Therapy: Methods, Pitfalls, and Challenges. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1117-1142.	0.4	86
92	Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy. Clinical and Translational Radiation Oncology, 2018, 12, 8-15.	0.9	11
93	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncology, The, 2018, 19, 1180-1191.	5.1	811
94	Radiobiology of brachytherapy: The historical view based on linear quadratic model and perspectives for optimization. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 312-318.	0.6	18
95	Anticancer chemotherapy and radiotherapy trigger both non-cell-autonomous and cell-autonomous death. Cell Death and Disease, 2018, 9, 716.	2.7	33
96	Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae. Oncotarget, 2018, 9, 9299-9310.	0.8	21
97	A review of uncertainties in radiotherapy dose reconstruction and their impacts on doseâ€“response relationships. Journal of Radiological Protection, 2017, 37, R1-R18.	0.6	22
98	Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors. Gynecologic Oncology, 2017, 144, 541-546.	0.6	22
99	Candidate immune biomarkers for radioimmunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 58-68.	3.3	14
100	Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. International Journal of Radiation Oncology Biology Physics, 2017, 99, 563-570.	0.4	39
101	Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 352-359.	0.4	47
102	Optimizing Local Control in Highâ€Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. Oncologist, 2017, 22, 182-188.	1.9	6
103	The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy. Molecular Cancer Therapeutics, 2017, 16, 2107-2119.	1.9	23
104	Assessment of the novel online delineation workshop dummy run approach using FALCON within a European multicentre trial in cervical cancer (RAIDs). Radiotherapy and Oncology, 2017, 124, 130-138.	0.3	7
105	NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy. Cell Death and Differentiation, 2017, 24, 1632-1644.	5.0	50
106	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discovery, 2017, 7, 586-595.	7.7	554
107	Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Annals of Oncology, 2017, 28, 1191-1206.	0.6	520
108	Pelvic radiotherapy in the setting of rheumatoid arthritis: Refining the paradigm. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 109-113.	0.6	3

#	Article	IF	Citations
109	Leukocytosis and neutrophilia predicts outcome in anal cancer. Radiotherapy and Oncology, 2017, 122, 137-145.	0.3	50
110	In Regard to Perrier etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 204-205.	0.4	1
111	Melanoma: Last call for radiotherapy. Critical Reviews in Oncology/Hematology, 2017, 110, 13-19.	2.0	39
112	Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Scientific Reports, 2017, 7, 7952.	1.6	71
113	Neutrophils, a candidate biomarker and target for radiation therapy?. Acta OncolÃ³gica, 2017, 56, 1522-1530.	0.8	50
114	Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy. Annals of Oncology, 2017, 28, 2691-2697.	0.6	7
115	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpointÂblockers (PD-1/PD-L1 inhibitors). European Journal of Cancer, 2017, 84, 202-211.	1.3	29
116	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. Brachytherapy, 2017, 16, 1021-1027.	0.2	11
117	Macrophage biology plays a central role during ionizing radiation-elicited tumor response. Biomedical Journal, 2017, 40, 200-211.	1.4	71
118	Pulsed-dose rate brachytherapy for pediatric bladder prostate rhabdomyosarcoma: Compliance and early clinical results. Radiotherapy and Oncology, 2017, 124, 285-290.	0.3	20
119	Bimodal fluorescence/129Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer. Bioorganic and Medicinal Chemistry, 2017, 25, 6653-6660.	1.4	12
120	Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. OncoImmunology, 2017, 6, e1341030.	2.1	36
121	Entosis: The emerging face of non-cell-autonomous type IV programmed death. Biomedical Journal, 2017, 40, 133-140.	1.4	42
122	External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation. Radiotherapy and Oncology, 2017, 124, 110-117.	0.3	26
123	Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. Oral Oncology, 2017, 71, 150-155.	0.8	92
124	Diffusion-weighted MRI in image-guided adaptive brachytherapy: Tumor delineation feasibility study and comparison with GEC-ESTRO guidelines. Brachytherapy, 2017, 16, 956-963.	0.2	13
125	First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. Clinical Cancer Research, 2017, 23, 908-917.	3.2	149
126	Concerns about cardiotoxicity in the HERA trial. Lancet, The, 2017, 390, 2767.	6.3	0

#	Article	IF	Citations
127	Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness. Frontiers in Immunology, 2017, 8, 613.	2.2	60
128	Relationships between Regional Radiation Doses and Cognitive Decline in Children Treated with Cranio-Spinal Irradiation for Posterior Fossa Tumors. Frontiers in Oncology, 2017, 7, 166.	1.3	20
129	Enhancement of IUdR Radiosensitization by Low-Energy Photons Results from Increased and Persistent DNA Damage. PLoS ONE, 2017, 12, e0168395.	1.1	10
130	Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?. , 2017, 5, 96.		6
131	Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. Journal of Gastrointestinal Oncology, 2017, 8, 173-179.	0.6	14
132	Locally advanced cervical cancer: Is it relevant to report image-guided adaptive brachytherapy using point A dose?. Brachytherapy, 2017, 16, 862-869.	0.2	7
133	Spectral and spatial shaping of a laser-produced ion beam for radiation-biology experiments. Physical Review Accelerators and Beams, 2017, 20, .	0.6	35
134	A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. Oncotarget, 2017, 8, 56199-56209.	0.8	8
135	Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget, 2017, 8, 11579-11588.	0.8	36
136	Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. Oncotarget, 2017, 8, 56210-56227.	0.8	17
137	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 25189-25199.	0.8	12
138	Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. Oncotarget, 2017, 8, 43169-43179.	0.8	100
139	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. Oncotarget, 2017, 8, 108786-108801.	0.8	22
140	Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. Oncotarget, 2016, 7, 25549-25557.	0.8	15
141	Patients aged over 75 years enrolled in Phase I clinical trials: the <scp>G</scp>ustave <scp>R</scp>oussy experience. International Journal of Cancer, 2016, 138, 875-880.	2.3	5
142	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. European Journal of Cancer, 2016, 62, 36-45.	1.3	105
143	Image-guided adaptive brachytherapy in cervical cancer: Patterns of relapse by brachytherapy planning parameters. Brachytherapy, 2016, 15, 456-462.	0.2	12
144	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. International Journal of Cardiology, 2016, 214, 364-369.	0.8	0

#	Article	IF	Citations
145	Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. Oral Oncology, 2016, 62, 153-162.	0.8	8
146	In Regard to Mattonen etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1544-1545.	0.4	17
147	PrPc deficiency and dasatinib protect mouse intestines against radiation injury by inhibiting of c-Src. Radiotherapy and Oncology, 2016, 120, 175-183.	0.3	7
148	Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. European Journal of Cancer, 2016, 66, 91-94.	1.3	54
149	Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy. Clinical and Experimental Metastasis, 2016, 33, 775-785.	1.7	6
150	Preoperative image-guided brachytherapy in early stage cervical cancers. Radiotherapy and Oncology, 2016, 120, 455-459.	0.3	14
151	Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?. Oral Oncology, 2016, 59, 50-57.	0.8	23
152	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncology, 2016, 62, 114-121.	0.8	43
153	Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. European Journal of Cancer, 2016, 68, 156-162.	1.3	113
154	Toxicity of concomitant cetuximab and radiotherapy with or without initial taxaneâ€based induction chemotherapy in locally advanced head and neck cancer. Head and Neck, 2016, 38, E905-10.	0.9	8
155	Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both?. Annals of Oncology, 2016, 27, 371-372.	0.6	4
156	Successes and Failures of Combined Modality Therapies in Head and Neck Cancer. Seminars in Radiation Oncology, 2016, 26, 299-306.	1.0	4
157	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
158	Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?. Cancer and Metastasis Reviews, 2016, 35, 277-288.	2.7	35
159	Nanoparticles in radiation oncology: From bench-side to bedside. Cancer Letters, 2016, 375, 256-262.	3.2	76
160	Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology, 2016, 90, 10-20.	0.9	4
161	Thirty years of phase I radiochemotherapy trials: Latest development. European Journal of Cancer, 2016, 58, 1-7.	1.3	13
162	Optimize and refine therapeutic index in radiation therapy: Overview of a century. Cancer Treatment Reviews, 2016, 45, 58-67.	3.4	60

#	Article	IF	Citations
163	Cardiac Diseases Following Childhood Cancer Treatment. Circulation, 2016, 133, 31-38.	1.6	87
164	Neutrophilia in locally advanced cervical cancer: A novel biomarker for image-guided adaptive brachytherapy?. Oncotarget, 2016, 7, 74886-74894.	0.8	36
165	From prospective biobanking to precision medicine: BIO-RAIDs â€“ an EU study protocol in cervical cancer. BMC Cancer, 2015, 15, 842.	1.1	16
166	Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. OncoTargets and Therapy, 2015, 8, 335.	1.0	16
167	Dosimetric Effects of the Interfraction Variations during Whole Breast Radiotherapy: A Prospective Study. Frontiers in Oncology, 2015, 5, 199.	1.3	5
168	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. Journal of Neuro-Oncology, 2015, 123, 307-314.	1.4	16
169	Risk of Subsequent Leukemia After a Solid Tumor in Childhood: Impact of Bone Marrow Radiation Therapy and Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 658-667.	0.4	15
170	Field size dependent mapping of medical linear accelerator radiation leakage. Physics in Medicine and Biology, 2015, 60, 2103-2116.	1.6	12
171	Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1223-1229.	0.6	45
172	Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. Radiotherapy and Oncology, 2015, 117, 364-375.	0.3	33
173	Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. Radiotherapy and Oncology, 2015, 114, 415-416.	0.3	35
174	Implementation of the global risk analysis in pulsed-dose rate brachytherapy: Methods and results. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 89-97.	0.6	2
175	18F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. Oral Oncology, 2015, 51, 370-375.	0.8	9
176	Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer. Molecular Cancer Therapeutics, 2015, 14, 1336-1345.	1.9	77
177	Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. Cancer Treatment Reviews, 2015, 41, 844-852.	3.4	110
178	Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British Journal of Cancer, 2015, 113, 1413-1420.	2.9	18
179	Thyroid Radiation Dose and Other Risk Factors of Thyroid Carcinoma Following Childhood Cancer. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4282-4290.	1.8	33
180	Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: A study based on patient specific artery segments dose calculation. Radiotherapy and Oncology, 2015, 117, 467-472.	0.3	51

#	Article	IF	Citations
181	Simultaneous Irradiation of Fibroblasts and Carcinoma Cells Repress the Secretion of Soluble Factors Able to Stimulate Carcinoma Cell Migration. PLoS ONE, 2015, 10, e0115447.	1.1	15
182	Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer. Cell Death and Disease, 2014, 5, e1423-e1423.	2.7	36
183	Focal or combined modality for the management of brain metastasis: did high tech radiotherapy superseded drug-radiotherapy combination?. Annals of Oncology, 2014, 25, 2293-2294.	0.6	2
184	Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?. Journal of Thoracic Oncology, 2014, 9, 7-17.	0.5	31
185	Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death and Differentiation, 2014, 21, 92-99.	5.0	181
186	Tribute to Professor Maurice Tubiana. International Journal of Radiation Oncology Biology Physics, 2014, 88, 755-756.	0.4	1
187	The use of radiotherapy for early breast cancer in woman at different ages. Clinical and Translational Oncology, 2014, 16, 680-685.	1.2	6
188	Improving safety in radiotherapy: The implementation of the Global Risk Analysis method. Radiotherapy and Oncology, 2014, 112, 205-211.	0.3	10
189	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. European Journal of Dermatology, 2014, 24, 265-267.	0.3	10
190	The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. British Journal of Radiology, 2014, 87, 20140134.	1.0	167
191	Post-chemoradiation intraoperative electron-beam radiation therapy boost in resected locally advanced rectal cancer: Long-term results focused on topographic pattern of locoregional relapse. Radiotherapy and Oncology, 2014, 112, 52-58.	0.3	14
192	In vivo biodistribution and oxygenation potential of a new generation of oxygen carrier. Journal of Biotechnology, 2014, 187, 1-9.	1.9	31
193	Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlentherapie Und Onkologie, 2014, 190, 823-831.	1.0	44
194	Functional Data Analysis in NTCP Modeling: A New Method to Explore the Radiation Dose-Volume Effects. International Journal of Radiation Oncology Biology Physics, 2014, 90, 654-663.	0.4	18
195	Epac contributes to cardiac hypertrophy and amyloidosis induced by radiotherapy but not fibrosis. Radiotherapy and Oncology, 2014, 111, 63-71.	0.3	26
196	Radiation therapy and immunotherapy: Implications for a combined cancer treatment. Critical Reviews in Oncology/Hematology, 2013, 85, 278-287.	2.0	61
197	Complications of thoracic radiotherapy. Presse Medicale, 2013, 42, e342-e351.	0.8	45
198	Combination of vascular disrupting agents and ionizing radiation. Critical Reviews in Oncology/Hematology, 2013, 86, 143-160.	2.0	39

#	Article	IF	Citations
199	Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Annals of Oncology, 2013, 24, 2834-2838.	0.6	78
200	A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. Investigational New Drugs, 2013, 31, 1530-1538.	1.2	22
201	Complications of chemotherapy, a basic science update. Presse Medicale, 2013, 42, e352-e361.	0.8	30
202	Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation. Drug Resistance Updates, 2013, 16, 10-21.	6.5	36
203	Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. European Journal of Cancer, 2013, 49, 1324-1334.	1.3	67
204	Targeted therapy-induced radiation recall. European Journal of Cancer, 2013, 49, 1662-1668.	1.3	55
205	The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Investigational New Drugs, 2013, 31, 273-284.	1.2	22
206	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer and Metastasis Reviews, 2013, 32, 479-492.	2.7	46
207	Editorial: Pannexin-1-the hidden gatekeeper for HIV-1. Journal of Leukocyte Biology, 2013, 94, 390-392.	1.5	20
208	The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell linesâ€™ in-vitro and in-vivo xenografts. Anti-Cancer Drugs, 2013, 24, 599-608.	0.7	12
209	IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy. Molecular Cancer Therapeutics, 2013, 12, 1213-1222.	1.9	40
210	Vemurafenib and Radiosensitization. JAMA Dermatology, 2013, 149, 855.	2.0	83
211	Controversies and challenges regarding the impact of radiation therapy on survival. Annals of Oncology, 2013, 24, 38-46.	0.6	39
212	Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials. Oncology Research and Treatment, 2013, 36, 357-362.	0.8	1
213	SU-E-T-279: Towards a Personalized Cardiovascular Dosimetry in Radiation Therapy. Medical Physics, 2013, 40, 268-268.	1.6	0
214	Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Annals of Oncology, 2012, 23, 1301-1306.	0.6	37
215	Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead. British Journal of Cancer, 2012, 107, 308-314.	2.9	38
216	MET targeting: perspectives for the radiation oncologist. Nature Reviews Clinical Oncology, 2012, 9, 548-548.	12.5	0

#	Article	IF	Citations
217	FOLFIRINOX in Locally Advanced Pancreatic Cancer. Pancreas, 2012, 41, 973-974.	0.5	3
218	Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy. Investigational New Drugs, 2012, 30, 2173-2186.	1.2	2
219	Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Investigational New Drugs, 2012, 30, 2318-2326.	1.2	20
220	Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?. Cancer and Metastasis Reviews, 2012, 31, 699-712.	2.7	41
221	Minimal residual disease in solid neoplasia: New frontier or red-herring?. Cancer Treatment Reviews, 2012, 38, 101-110.	3.4	19
222	Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncology, 2012, 8, 1167-1181.	1.1	277
223	Stem cell tracking: toward clinical application in oncology?. Tumori, 2012, 98, 535-42.	0.6	4
224	Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treatment Reviews, 2011, 37, 476-86.	3.4	29
225	Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Letters, 2011, 312, 209-218.	3.2	40
226	Cancer Stem Cells. Journal of Oncology, 2011, 2011, 1-1.	0.6	4
227	Lung Cancer Stem Cell: New Insights on Experimental Models and Preclinical Data. Journal of Oncology, 2011, 2011, 1-10.	0.6	30
228	Radiosensitivity of Human Papillomavirusâ€“Related Tumors: In Regard to Gupta etÂal. (Int J Radiat Oncol) Tj ETQq0 0 0 rgBT /Overlock	0.4	0
229	Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?. Annals of Oncology, 2011, 22, 1247-1249.	0.6	16
230	Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: still to be established. European Journal of Cardio-thoracic Surgery, 2011, 39, 427-428.	0.6	1
231	Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?. Annals of Oncology, 2011, 22, 485-486.	0.6	20
232	Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells. PLoS ONE, 2011, 6, e26073.	1.1	41
233	BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. British Journal of Cancer, 2010, 103, 347-353.	2.9	27
234	What Have We Learned From Human Papillomavirusâ€“Positive Tumors? Trying to Connect Data About Biomarkers Among Human Papillomavirusâ€“Related Squamous Cell Carcinomas. Journal of Clinical Oncology, 2010, 28, e340-e341.	0.8	2

#	Article	IF	Citations
235	Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination. Molecular Cancer Therapeutics, 2010, 9, 358-368.	1.9	44
236	Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity. Cancer Treatment Reviews, 2010, 36, 629-636.	3.4	21
237	Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Anticancer Research, 2010, 30, 3869-78.	0.5	16
238	Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints. Cell Cycle, 2009, 8, 1196-1205.	1.3	54
239	The Aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle, 2009, 8, 3172-3181.	1.3	49
240	Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both?. Annals of Oncology, 2009, 20, 596-597.	0.6	1
241	Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2009, 27, 1100-1107.	0.8	71
242	Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma. Cell Proliferation, 2009, 42, 38-48.	2.4	13
243	Concomitant chemo-radiotherapy in clinical trials: To promote step by step rational development. Critical Reviews in Oncology/Hematology, 2009, 70, 206-215.	2.0	6
244	Differential Effect Triggered by a Heparan Mimetic of the RGTA Family Preventing Oral Mucositis Without Tumor Protection. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1242-1250.	0.4	20
245	Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nature Reviews Clinical Oncology, 2009, 6, 528-534.	12.5	79
246	Oncologic and Functional Results After Abdominoperineal Resection Plus Pseudocontinent Perineal Colostomy for Epidermoid Carcinoma of the Anus. Diseases of the Colon and Rectum, 2009, 52, 958-963.	0.7	30
247	Novel Anti-Metastatic Action of Cidofovir Mediated by Inhibition of E6/E7, CXCR4 and Rho/ROCK Signaling in HPV+ Tumor Cells. PLoS ONE, 2009, 4, e5018.	1.1	42
248	Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents. Cancer and Metastasis Reviews, 2008, 27, 737-750.	2.7	11
249	Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene, 2008, 27, 3244-3255.	2.6	79
250	A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatment. Gastroenterologie Clinique Et Biologique, 2008, 32, 649-652.	0.9	0
251	The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. European Journal of Cancer, 2008, 44, 2133-2143.	1.3	24
252	Essential Role of Plasminogen Activator Inhibitor Type-1 in Radiation Enteropathy. American Journal of Pathology, 2008, 172, 691-701.	1.9	47

#	Article	IF	Citations
253	MVP and vinorelbine for malignant pleural mesothelioma. Lancet, The, 2008, 372, 629.	6.3	3
254	Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity. Cancer Research, 2008, 68, 5915-5923.	0.4	124
255	Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Annals of Oncology, 2008, 19, 787-792.	0.6	95
256	Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nature Clinical Practice Oncology, 2008, 5, 268-278.	4.3	96
257	Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. British Journal of Cancer, 2007, 97, 1664-1672.	2.9	66
258	Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathwayâ€"therapeutic perspectives in cancer. Nature Clinical Practice Oncology, 2007, 4, 591-602.	4.3	217
259	Radiotherapy for localized rectal cancer. Annals of Oncology, 2007, 18, ix105-ix113.	0.6	4
260	Pancreatic cancer: From pathogenesis to cure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 997-1014.	1.0	11
261	Hemodynamic and respiratory changes following dexmedetomidine administration during general anesthesia: sevoflurane vs desflurane. Paediatric Anaesthesia, 2007, 17, 438-444.	0.6	57
262	Influence of Endothelial Cells on Vascular Smooth Muscle Cells Phenotype after Irradiation. American Journal of Pathology, 2006, 169, 1484-1495.	1.9	125
263	Caspase independence of radio-induced cell death. Oncogene, 2006, 25, 7758-7770.	2.6	27
264	Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines.. Cancer Biology and Therapy, 2006, 5, 1206-1210.	1.5	11
265	Tumour stem cell-targeted treatment: elimination or differentiation. Annals of Oncology, 2006, 17, 1620-1624.	0.6	150
266	Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Molecular Cancer Therapeutics, 2005, 4, 1717-1728.	1.9	89
267	New concepts for phase I trials: evaluating new drugs combined with radiation therapy. Nature Clinical Practice Oncology, 2005, 2, 456-465.	4.3	22
268	Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. British Journal of Cancer, 2004, 91, 1735-1741.	2.9	35
269	Gene Expression Profile in Human Late Radiation Enteritis Obtained by High-Density cDNA Array Hybridization. Radiation Research, 2004, 161, 299-311.	0.7	65
270	Endothelial-cell apoptosis and tumour response to radiotherapy. Lancet Oncology, The, 2004, 5, 9.	5.1	5

#	Article	IF	Citations
271	Environmental, genetic, and molecular features of prostate cancer. Lancet Oncology, The, 2004, 5, 303-313.	5.1	67
272	n-3 Polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis. British Journal of Cancer, 2003, 89, 1102-1107.	2.9	45
273	Antiviral agent Cidofovir decreases Epsteinâ€“Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene, 2003, 22, 2260-2271.	2.6	50
274	Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene, 2003, 22, 7905-7912.	2.6	43
275	Chemoprevention of lung cancer. Lancet Oncology, The, 2003, 4, 659-669.	5.1	52
276	Cyclooxygenase-2 Inhibitor NS398 Enhances Antitumor Effect of Irradiation on Hormone Refractory Human Prostate Carcinoma Cells. Journal of Urology, 2003, 170, 2036-2039.	0.2	28
277	Sensitivity to Radiation and Alkylating Agent of Peripheral Lymphocytes and Fibroblasts in a Hoyeraal-Hreidarsson Syndrome Patient. Pediatric Hematology and Oncology, 2003, 20, 651-656.	0.3	14
278	Down-regulation of BRCA1 in BCR-ABLâ€“expressing hematopoietic cells. Blood, 2003, 101, 4583-4588.	0.6	94
279	Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Research, 2003, 63, 2513-7.	0.4	51
280	Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene, 2002, 21, 2334-2346.	2.6	121
281	BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood, 2001, 97, 2084-2090.	0.6	155
282	Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. British Journal of Cancer, 2001, 85, 2017-2021.	2.9	97
283	A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1105-1108.	0.4	90
284	Decreased DNA-PK activity in human cancer cells exhibiting hypersensitivity to low-dose irradiation. British Journal of Cancer, 2000, 83, 514-518.	2.9	54
285	Spontaneous Spinal Epidural Hematoma With Spinal Cord Compression Complicating Plasma Cell Myeloma. Spine, 1998, 23, 2432-2435.	1.0	22
286	Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.. Circulation, 1990, 82, 2044-2051.	1.6	567